No Data
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
Regeneron Announces Investor Conference Presentations